{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T18:57:13Z","timestamp":1795201033420,"version":"4.10.3"},"reference-count":33,"publisher":"American Society of Hematology","issue":"18","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Treatment with direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) is effective and safe. However, bleeding complications still occur. Whether DOAC level measurement may further improve treatment efficacy and safety is still an open issue. In the \"Measure and See\" study, venous blood was collected 15-30\u00a0days after DOAC initiation in patients with AF who were then followed up for 1 year to record the occurrence of major and clinically relevant nonmajor bleeding. DOAC plasma levels were measured in 1 laboratory, and results were kept blind to patients and treating doctors. Trough DOAC levels were assessed in 1657 patients (957 [57.7%] and 700 patients treated with standard and low-dose, respectively). Fifty bleeding events were recorded during 1606 years of follow-up (3.11% pt\/yrs). Fifteen bleeding events (4.97% pt\/yrs) occurred in patients with C-trough standardized values in the highest activity class (&amp;gt;0.50), whereas 35 events (2.69% pt\/yrs) occurred in those with values in the 2 lower classes (\u22640.50, P\u00a0=\u00a0.0401). Increasing DOAC levels and low-dose DOAC use were associated with increased bleeding risk in the first 3\u00a0months of treatment. Overall, 19% of patients receiving low doses had standardized values in the highest class. More bleeding occurred in patients on low (4.3% pt\/yrs) vs standard (2.2% pt\/yrs; P\u00a0=\u00a0.0160) dose DOAC. Early measurement of DOAC levels in patients with AF identified many individuals with high levels despite the low doses use and had\u00a0more bleeding risk during the first 3\u00a0months of treatment. This trial was registered at www.ClinicalTrials.gov as #NCT03803579.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013126","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T09:57:51Z","timestamp":1717667871000},"page":"4913-4923","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":32,"title":["More early bleeds associated with high baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4327-9561","authenticated-orcid":false,"given":"Gualtiero","family":"Palareti","sequence":"first","affiliation":[{"name":"1Fondazione Arianna Anticoagulazione, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Testa","sequence":"additional","affiliation":[{"name":"2Centro Emostasi e Trombosi, Laboratorio Analisi Chimico-Cliniche e Microbiologiche, ASST Cremona, Cremona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1999-7800","authenticated-orcid":false,"given":"Cristina","family":"Legnani","sequence":"additional","affiliation":[{"name":"1Fondazione Arianna Anticoagulazione, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5704-953X","authenticated-orcid":false,"given":"Claudia","family":"Dellanoce","sequence":"additional","affiliation":[{"name":"2Centro Emostasi e Trombosi, Laboratorio Analisi Chimico-Cliniche e Microbiologiche, ASST Cremona, Cremona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9681-6159","authenticated-orcid":false,"given":"Michela","family":"Cini","sequence":"additional","affiliation":[{"name":"1Fondazione Arianna Anticoagulazione, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4927-0031","authenticated-orcid":false,"given":"Oriana","family":"Paoletti","sequence":"additional","affiliation":[{"name":"2Centro Emostasi e Trombosi, Laboratorio Analisi Chimico-Cliniche e Microbiologiche, ASST Cremona, Cremona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ciampa","sequence":"additional","affiliation":[{"name":"3Centro Emostasi, UOC Laboratorio Analisi, Ospedale S.G. Moscati, Avellino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9185-2046","authenticated-orcid":false,"given":"Emilia","family":"Antonucci","sequence":"additional","affiliation":[{"name":"1Fondazione Arianna Anticoagulazione, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Poli","sequence":"additional","affiliation":[{"name":"4Malattie Aterotrombotiche, AOU Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0025-1770","authenticated-orcid":false,"given":"Rossella","family":"Morandini","sequence":"additional","affiliation":[{"name":"2Centro Emostasi e Trombosi, Laboratorio Analisi Chimico-Cliniche e Microbiologiche, ASST Cremona, Cremona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5842-9036","authenticated-orcid":false,"given":"Maurizio","family":"Tala","sequence":"additional","affiliation":[{"name":"2Centro Emostasi e Trombosi, Laboratorio Analisi Chimico-Cliniche e Microbiologiche, ASST Cremona, Cremona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Chiarugi","sequence":"additional","affiliation":[{"name":"5UO di Analisi Chimico Cliniche, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5081-8201","authenticated-orcid":false,"given":"Rita Carlotta","family":"Santoro","sequence":"additional","affiliation":[{"name":"6Centro Emostasi e Trombosi, UO Emofilia e Patologie della Coagulazione, Dipartimento di Ematologia, Oncologia e Medicina Trasfusionale, Azienda Ospedaliera \"Pugliese Ciaccio,\" Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Maria","family":"Iannone","sequence":"additional","affiliation":[{"name":"7UOSVD Sezione Trasfusionale, Ospedale Don Tonino Bello, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0942-2819","authenticated-orcid":false,"given":"Erica","family":"De Candia","sequence":"additional","affiliation":[{"name":"8UOSD Malattie Emorragiche e Trombotiche, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2265-7455","authenticated-orcid":false,"given":"Pasquale","family":"Pignatelli","sequence":"additional","affiliation":[{"name":"9UOC Medicina Interna e Prevenzione dell\u2019Aterosclerosi, Dipartimento di Medicina Interna e Specialit\u00e0 Mediche, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8731-6531","authenticated-orcid":false,"given":"Elena Maria","family":"Faioni","sequence":"additional","affiliation":[{"name":"10Servizio Immunologia e Medicina Trasfusionale, Ospedale San Paolo, ASST Santi Paolo e Carlo, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2593-1376","authenticated-orcid":false,"given":"Antonio","family":"Chistolini","sequence":"additional","affiliation":[{"name":"11UO Medicina Traslazionale e di Precisione, Dipartimento Medicina Interna e Specialit\u00e0 Mediche, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria del Pilar","family":"Esteban","sequence":"additional","affiliation":[{"name":"12UO Laboratorio Analisi, Dipartimento dei Servizi Diagnostici, Ospedale Oglio Po, ASST Cremona, Cremona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Marietta","sequence":"additional","affiliation":[{"name":"13Struttura Complessa di Ematologia, Policlinico di Modena, Azienda Ospedaliera Universitaria di Modena, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Tripodi","sequence":"additional","affiliation":[{"name":"14Centro Emofila e Trombosi Angelo Bianchi Bonomi, presso la Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0119-5204","authenticated-orcid":false,"given":"Alberto","family":"Tosetto","sequence":"additional","affiliation":[{"name":"15UOC Ematologia, Centro Malattie Emorragiche e Trombotiche, AULSS 8 Berica Ospedale S. Bortolo, Vicenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"issue":"12","key":"2024092412004813900_bib1","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2024092412004813900_bib2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2024092412004813900_bib3","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"2024092412004813900_bib4","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024092412004813900_bib5","doi-asserted-by":"crossref","first-page":"e005835","DOI":"10.1161\/JAHA.117.005835","article-title":"Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis","volume":"6","author":"Pan","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"4","key":"2024092412004813900_bib6","doi-asserted-by":"crossref","first-page":"E877","DOI":"10.9778\/cmajo.20200055","article-title":"Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study","volume":"8","author":"Durand","year":"2020","journal-title":"CMAJ Open"},{"issue":"3","key":"2024092412004813900_bib7","doi-asserted-by":"crossref","first-page":"e005894","DOI":"10.1161\/CIRCOUTCOMES.119.005894","article-title":"Effectiveness and safety of direct oral anticoagulants in relation to temporal changes in their use","volume":"13","author":"Lee","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"4","key":"2024092412004813900_bib8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"issue":"12","key":"2024092412004813900_bib9","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1161\/STROKEAHA.118.020232","article-title":"Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients","volume":"49","author":"Lip","year":"2018","journal-title":"Stroke"},{"issue":"8","key":"2024092412004813900_bib10","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1182\/bloodadvances.2023012408","article-title":"Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillations: the MAS study","volume":"8","author":"Testa","year":"2024","journal-title":"Blood Adv"},{"issue":"5","key":"2024092412004813900_bib11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1055\/s-0039-1692700","article-title":"Preanalytical variables in coagulation testing: setting the stage for accurate results","volume":"45","author":"Gosselin","year":"2019","journal-title":"Semin Thromb Hemost"},{"key":"2024092412004813900_bib12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.thromres.2017.05.005","article-title":"Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay","volume":"155","author":"He","year":"2017","journal-title":"Thromb Res"},{"issue":"2","key":"2024092412004813900_bib13","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/ijlh.13159","article-title":"DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-register","volume":"42","author":"Cini","year":"2020","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"2024092412004813900_bib14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/ijlh.14166","article-title":"Comparisons between diluted thrombin time, ecarin chromogenic assays, and UPLC-MS for plasma level dabigatran quantification: results from DRIVING study","volume":"46","author":"de Fautereau-Vassel","year":"2023","journal-title":"Int J Lab Hematol"},{"issue":"4","key":"2024092412004813900_bib15","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"issue":"11","key":"2024092412004813900_bib16","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"issue":"9025","key":"2024092412004813900_bib17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(96)01109-9","article-title":"Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian study on complications of oral anticoagulant therapy","volume":"348","author":"Palareti","year":"1996","journal-title":"Lancet"},{"issue":"16","key":"2024092412004813900_bib18","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"issue":"5","key":"2024092412004813900_bib19","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/bcp.12106","article-title":"Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects","volume":"76","author":"Frost","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"2024092412004813900_bib20","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40262-015-0342-7","article-title":"Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa","volume":"55","author":"Parasrampuria","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"2024092412004813900_bib21","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.thromres.2015.12.001","article-title":"Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: results observed in four anticoagulation clinics","volume":"137","author":"Testa","year":"2016","journal-title":"Thromb Res"},{"key":"2024092412004813900_bib22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.thromres.2019.01.008","article-title":"Edoxaban plasma levels in patients with non-valvular atrial fibrillation: inter and intra-individual variability, correlation with coagulation screening test and renal function","volume":"175","author":"Testa","year":"2019","journal-title":"Thromb Res"},{"issue":"5","key":"2024092412004813900_bib23","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/bjh.17899","article-title":"Assessment of exposure to direct oral anticoagulants in elderly hospitalised patients","volume":"195","author":"Kampouraki","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"2024092412004813900_bib24","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/jth.15563","article-title":"Inter- and intra-individual concentrations of direct oral anticoagulants: the KIDOAC study","volume":"20","author":"Toorop","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"2024092412004813900_bib25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40262-023-01222-w","article-title":"Insights into the pharmacokinetics and pharmacodynamics of direct oral anticoagulants in older adults with atrial fibrillation: a structured narrative review","volume":"62","author":"Edwina","year":"2023","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"2024092412004813900_bib26","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/jth.13344","article-title":"To measure or not to measure direct oral anticoagulants before surgery or invasive procedures","volume":"14","author":"Tripodi","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"issue":"8","key":"2024092412004813900_bib27","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1055\/a-1450-8178","article-title":"2021 Update of the International council for standardization in haematology recommendations for laboratory measurement of direct oral anticoagulants","volume":"121","author":"Douxfils","year":"2021","journal-title":"Thromb Haemost"},{"issue":"10","key":"2024092412004813900_bib28","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"issue":"4","key":"2024092412004813900_bib29","doi-asserted-by":"crossref","first-page":"e007633","DOI":"10.1161\/JAHA.117.007633","article-title":"Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants: results from ORBIT-AF II (the outcomes registry for better informed treatment of atrial fibrillation II)","volume":"7","author":"Steinberg","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"3","key":"2024092412004813900_bib30","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/bcp.14127","article-title":"Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: a systematic review","volume":"86","author":"Santos","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"2024092412004813900_bib31","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/jamacardio.2016.1841","article-title":"Appropriate apixaban dosing: prescribers take note","volume":"1","author":"Weitz","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"12","key":"2024092412004813900_bib32","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.jacc.2020.07.045","article-title":"Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants","volume":"76","author":"Camm","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"2024092412004813900_bib33","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1160\/TH16-07-0494","article-title":"Real-life treatment of venous thromboembolism with direct oral anticoagulants: the influence of recommended dosing and regimens","volume":"117","author":"Trujillo-Santos","year":"2017","journal-title":"Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/18\/4913\/2243725\/blooda_adv-2024-013126-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/18\/4913\/2243725\/blooda_adv-2024-013126-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T09:44:03Z","timestamp":1727171043000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/18\/4913\/516363\/More-early-bleeds-associated-with-high-baseline"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":33,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024,9,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013126","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]}}}